Background: Interleukin (IL)-13 plays a key role in type 2 inflammation and is an emerging pathogenic mediator in atopic dermatitis (AD).
Atopic dermatitis (AD) is a chronic skin disorder characterized by intensely pruritic, eczematous lesions accompanied by a disrupted skin barrier and type 2 inflammation. 1 AD is one of the most common dermatologic diagnoses worldwide and its burden is multidimensional, impacting sleep, psychosocial activities, and health-related quality of life. [2] [3] [4] In moderate-to-severe AD, potent topical corticosteroids (TCS), calcineurin inhibitors, phototherapy, and conventional immunosuppressive medications (eg, cyclosporine) are often required. However, efficacy of topical therapies can be limited, and their frequent use is cumbersome and carries the risk for side effects. 5 Standard systemic treatments used for moderate-to-severe disease also carry significant risks. 6 Interleukin (IL)-13 plays a central role in type 2 inflammation, and certain gene polymorphisms are associated with increased risk for AD. 7 There is increased expression of IL-13 mRNA in skin biopsy specimens from patients with AD relative to healthy controls, and levels of IL-13 mRNA expression correlate with AD disease severity. 8, 9 Furthermore, overexpression of IL-13 has been shown to reduce epithelial integrity via the down-regulation of key skin barrier components. 10, 11 Treatment of AD with systemic agents such as cyclosporine can decrease skin IL-13 levels, 12 and recent trials have reported improved clinical responses in patients with moderate-to-severe AD treated with dupilumab, a monoclonal antibody against IL-4Ra, which inhibits IL-13/ IL-4 signaling. 13, 14 Together, these data support IL-13 as a key mediator in AD.
In theory, targeting the most central pathologic mediators in AD might maximize efficacy and limit toxicity. Lebrikizumab is a monoclonal antibody that binds specifically to soluble IL-13 with high affinity, preventing IL-13Ra1/IL4Ra heterodimerization and subsequent signaling. 15, 16 Lebrikizumab has previously been investigated for the treatment of asthma, and data have accumulated from 11 randomized clinical trials involving 4411 individuals. 15, [17] [18] [19] [20] After promising phase 2b data in uncontrolled asthma, only 1 of the 2 phase 3 studies in severe adult asthma showed a statistically significant reduction in asthma exacerbations in the primary analysis population. Nonetheless, based on IL-13's involvement in multiple pathways important to AD pathogenesis, lebrikizumab represents a novel targeted therapy in AD.
CAPSULE SUMMARY d
Interleukin 13 (IL-13) is overexpressed in patients with atopic dermatitis (AD). Lebrikizumab, a monoclonal antibody against IL-13, was superior to placebo in patients with AD when administered subcutaneously every 4 weeks along with topical corticosteroids. d IL-13 inhibition with lebrikizumab could reduce the need for oral immunosuppressive therapy for patients with AD.
In this proof-of-concept phase 2 study, we investigated the efficacy and safety of lebrikizumab, compared with placebo, as an add-on therapy to TCS in adults with moderate-to-severe AD.
METHODS

Study design
TREBLE was a randomized, placebo-controlled, double-blind, phase 2 study conducted at 62 centers. It included a 2-week TCS run-in period before the 12-week treatment period. Patients were instructed with daily e-Diary reminders to apply medium-potency TCS (0.1% triamcinolone acetonide) to all lesional skin during run-in and study treatment. For lesions affecting the face or intertriginous areas, 2.5% hydrocortisone could be used. TCS was included in the regimen because, historically, studies on biologic therapies in a monotherapy setting have led to high dropout/imputed patient failure rates, in particular because of disease severity. In addition, add-on TCS treatment reflects real-life clinical practice in patients with moderate-to-severe AD. Further details about study design, pharmacokinetics, outcome measures, and statistical analyses are provided in the online Supplementary Appendix (available at http://www. jaad.org). The study was undertaken in accordance with Good Clinical Practice guidelines and adhered to the Declaration of Helsinki. All study documents and procedures were approved by the appropriate institutional review boards and ethics committees at each study site and each patient provided written informed consent before study participation. An internal monitoring committee was incorporated to monitor patient safety throughout the study.
Patients
Eligible patients were aged 18-75 years and had a diagnosis of moderate-to-severe AD with an inadequate response to TCS ($1-month history within 3 months before screening) and regular emollient. Other key inclusion criteria were Eczema Area and Severity Index (EASI) $14 and Investigator Global Assessment (IGA) score $3 at screening and end of the run-in period and AD involvement of $10% of body surface area (BSA) and Pruritus Visual Analog Scale (VAS) score $3 (measured as part of SCORing Atopic Dermatitis [SCORAD]) at screening.
Exclusion criteria included use of topical calcineurin inhibitors; recent systemic immunosuppressive therapies or phototherapy; and evidence of other skin conditions, including T-cell lymphoma or allergic contact dermatitis.
Randomization
Patients were randomized 1:1:1:1 to receive lebrikizumab 125 mg single dose at baseline, 250 mg single dose at baseline, 125 mg once every 4 weeks, or placebo every 4 weeks for 12 weeks.
Procedures
The 12-week treatment period was followed by an 8-week safety follow-up period, during which patients could apply TCS as needed. Disease severity assessments included EASI, IGA, and SCORAD; patient-reported outcome data were collected by using the Dermatology Life Quality Index and AD Impact Questionnaire (ADIQ).
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Outcomes
The primary endpoint was the percentage of patients achieving a 50% reduction in EASI score from baseline (EASI-50) at week 12. This EASI-50 also equates to a minimum of a 7-point improvement from the required baseline score $14 in this study, which is above the minimum clinically important difference of 6.6 points.
22 Key secondary endpoints included the percentages of patients achieving EASI-75, IGA score of 0 or 1, and SCORAD-50 at week 12. Safety outcomes, including treatment-emergent adverse events (AEs) and serious AEs, were monitored at each visit from baseline to week 20. Eosinophil-associated AEs were also monitored.
Statistical analyses
Primary and secondary efficacy analyses included all patients who were randomized and received $1 dose of study drug and were analyzed according to the treatment assigned at randomization. Safety analyses included all patients who received $1 dose of study drug and were analyzed according to the treatment received. The Cochran-Mantele Haenszel x 2 test was used to compare the proportions of patients with EASI-50 at week 12 in each of the lebrikizumab groups versus placebo, stratified by randomization stratification factor 
RESULTS
Trial patients
Overall, 209 patients received study drug (n = 53 placebo; n = 156 lebrikizumab) (Supplemental Fig 1; available at http://www.jaad.org). Baseline characteristics of patients were similar across treatment groups (Table I ). There was a high compliance rate of TCS use among all treatment groups, with TCS used on average from baseline to week 12 on 86.8% of days for patients taking the 125-mg single dose, 86.7% of days for patients taking the 250-mg single dose, 91.9% of days for patients taking the 125-mg dose every 4 weeks, and 88.2% of days for patients taking placebo. Further details of the results are provided in the online Supplementary Appendix.
Primary outcome
At week 12, significantly more patients in the lebrikizumab 125 mg every 4 weeks group achieved EASI-50 compared with placebo (82.4% vs 62.3%; P = .026) (Fig 1, A) . However, the response in the lebrikizumab single dose groups was not statistically significant at week 12. In the every 4 weeks arm, the response curve showed an upward sloping trajectory in the final weeks of treatment (Fig 2, A) . Notably, patients in the placebo group, with protocolmandated twice daily TCS application, showed a high response rate, with 62.3% of patients exhibiting an EASI-50 response at week 12.
Other AD severity measures
The proportion of patients achieving an EASI-75 response at week 12 was significantly greater in the 125 mg every 4 weeks group (54.9%; P = .036) compared with placebo (34.0%) but did not achieve statistical significance in the 125 mg and 250 mg single dose groups (Fig 1, B) . As with the EASI-50 response, patients in the 125 mg every 4 weeks group showed continued improvement in EASI-75 over the final weeks of the treatment period (Fig 2, B) .
The percentage of patients who achieved an IGA of 0 or 1 at week 12 was higher in all lebrikizumab groups compared with placebo (Fig 1, C; Fig 2, C ) , but while there was a trend toward statistical significance with the 125 mg every 4 weeks group compared with placebo (33.3% vs 18.9%; P = .098), single doses did not achieve statistical significance (Supplemental Table I ; available at http://www.jaad.org).
SCORAD-50 at week 12 was achieved by more patients in the lebrikizumab 125 mg every 4 weeks group (51.0%; P = .012) and 250 mg single dose group (47.2%; P = .030) than the placebo group (26.4%) (Fig 1, D; Fig 2, D) . The greatest reduction in BSA affected at week 12 was observed in the lebrikizumab 125 mg every 4 weeks group (57.7% reduction). Because there were also improvements in BSA affected in the placebo group (47.4%), placebo-corrected efficacy for BSA was not statistically significant (P = .38).
Patient-reported symptoms and quality of life
There were adjusted mean percent reductions from baseline pruritus VAS of 34.9%, 32.8%, and 40.7% in the lebrikizumab 125 mg single dose, 250 mg single dose, and 125 mg every 4 weeks groups, respectively (Fig 3, A) . The placebo group also showed reductions from baseline pruritus VAS (27.5%), which resulted in the placebo-corrected efficacy not being statistically significant (P = .40 
10 (19) 15 (28) 11 (22) 11 (21 Table I ; available at http://www.jaad.org). Improvements in pruritus VAS during the 2-week TCS run-in were quantitatively larger, in percentage terms, than improvements in overall disease severity measures (Supplemental Table II ). There were also improvements in sleep loss VAS, with higher mean reductions from baseline in the lebrikizumab 125 mg single dose (53.1%; P = .029), 250 mg single dose (47.2%; P = .076), and 125 mg every 4 weeks (53.6%; P = .023) groups than in the placebo group (22.6%) (Fig 3, B ; Supplemental Table I) .
Lebrikizumab groups showed numerical improvements, relative to placebo, in ADIQ and Dermatology Life Quality Index scores from baseline to week 12, with ADIQ showing borderline statistical significance for the 125 mg every 4 weeks group (P = .057), but results were otherwise not statistically significant (Fig 3, C and D; Supplemental Table I ).
Safety
Lebrikizumab was well tolerated, and there were no imbalances in proportions of patients reporting AEs, serious AEs, events leading to discontinuation, and overall infections when comparing all lebrikizumab-treated patients with placebo (Supplemental Table III ; available at http://www.jaad.org). There were no doseresponse relationships in adverse events. Three (2%) patients in the lebrikizumab group (all doses combined) and 1 (2%) patient in the placebo group experienced an AE that led to withdrawal from study. There were no deaths, anaphylactic reactions, malignancies, or protocol-defined parasitic or targeted intracellular infections of interest. Injection site reactions occurred infrequently (1.3% all lebrikizumab groups and 1.9% placebo group); all events were nonserious and lasted a median of 1-3 days. 
DISCUSSION
Lebrikizumab provided a treatment benefit on top of rigorous TCS therapy in patients with moderateto-severe AD who had an inadequate response to TCS. The study met its primary endpoint, with a statistically greater proportion of patients in the lebrikizumab 125 mg every 4 weeks group achieving an EASI-50 response compared with placebo. The upward sloping response curves over the final weeks of the treatment period suggest that the response plateau might not have been reached by week 12 for lebrikizumab 125 mg every 4 weeks, and that a longer treatment duration might lead to improved efficacy. Although improvements with the single doses were not statistically significant at week 12, the significant responses observed with the highest lebrikizumab dose (125 mg every 4 weeks) might indicate a dose-response relationship.
Dosing within this study was based largely on experience from the lebrikizumab asthma program and the objective of characterizing both doseresponse relationships and dosing frequency requirements in AD. The dose-response relationships observed across multiple endpoints and the trends toward improved efficacy with increasing dose and duration suggest that further increases in the dose or treatment duration could improve efficacy. Notably, the lebrikizumab 250 mg single dose group showed numerically higher responses at earlier time points for several outcomes, suggesting the potential benefit of either higher dosing (eg, 250 mg every 4 weeks) or a loading dose. The observed differences in the lebrikizumab doseresponse relationship between forced expiratory volume in 1 second in asthma patients 17 and EASI and IGA endpoints in AD patients suggest that AD might require higher doses of lebrikizumab to achieve a response plateau. This would suggest a higher IL-13 burden in AD than in asthma. Further studies in AD will be required to confirm whether additional clinical benefit can be observed with tailored dosing.
Lebrikizumab was generally well tolerated, and AE rates were similar between treatment groups. This safety profile is consistent with that observed in the extensive asthma program. 15, [17] [18] [19] [20] Previously reported increases in peripheral blood eosinophil counts with lebrikizumab treatment are possibly due to decreased eosinophil trafficking from the blood to the airways as a result of reduced chemotaxis by blocking IL-13 activity. 15, 20 In the TREBLE study, although eosinophil-associated AEs occurred only among lebrikizumab-treated patients, they were reported infrequently (n = 5 [3.2%] ), all events were nonserious, and none were associated with clinical signs or symptoms, or resulted in dose reductions or treatment discontinuation.
The study protocol required twice daily TCS during the 2-week run-in period, and patients were only eligible for randomization if they manifested sufficient AD severity after this run-in. Although patients included in this study had a history of inadequate control by TCS, this TCS run-in nonetheless led to disease improvement, with lower baseline AD severity scores, especially itch. Although there is rationale for such a design, it does potentially leave less room for disease improvement than without a run-in period.
During the treatment period, patients continued twice-daily application of TCS, with daily e-Diary reminders, achieving an 88% compliance rate. TCS application might explain the substantial response observed in placebo and could also have attenuated placebo-corrected efficacy. Prolonged and frequent TCS use has been shown to result in progressive improvements in AD, but most guidelines suggest limiting daily use to avoid AEs. [23] [24] [25] However, while daily (not chronic) TCS use is typically recommended for acute lesions, 5 this proof-of-concept study sought to understand the potential efficacy of lebrikizumab in addition to continuous TCS and not to assess TCS-sparing. The chosen regimen is consistent with TCS labeling and was used because of regulatory concerns of off-label usage at a lower frequency than mandated by product labeling. It was also recognized that alternate designs could have led to substantial patient dropout and imputed patient failure within the control arm. Indeed, studies of biologic therapies in a monotherapy setting have led to dropout/imputed patient failure rates of ;50% within the control arm 13 ; in contrast, the dropout rate of the placebo arm in this study was 13%. Nonetheless, despite the relatively high efficacy of prolonged and frequent TCS use, there were still significant improvements, particularly in AD signs (EASI) and global scores (SCORAD) after addition of lebrikizumab. Dupilumab, an IL-4Ra monoclonal antibody, demonstrated efficacy in patients with moderateto-severe AD and has been recently approved for use in AD patients. IL-4Ra is a receptor subunit for both IL-4 and IL-13 signaling. Studies of dupilumab in AD patients provide insight into the potential of IL-13 blockade to treat AD, with the caveat that the relative importance of IL-4 compared with IL-13 in AD has not been established. Both IL-13 and IL-4 share overlapping biology and effector functions. 26, 27 Given such high overlap in biology, blockade of IL-13 alone could potentially provide comparable improvements in AD to blockade of IL-13 and IL-4 in combination, with a more specific targeted action.
Targeting a soluble cytokine such as IL-13 might also offer the advantage of a linear pharmacokinetic profile, with resulting improvements in sustained target coverage and dosing frequency. This linear pharmacokinetic profile combined with the long half-life of lebrikizumab (19-22 days), in part, explains the ability to dose lebrikizumab every 4 weeks and might allow for less frequent dosing during maintenance. Indeed, the fact that single-dose groups showed improving placebo-corrected efficacy through week 8 suggests the potential for such a dosing regimen. In contrast, receptor targeting is associated with target-mediated drug clearance, which might lead to rapid declines in concentration after drug discontinuation or interruption, as with dupilumab, which is dosed every 2 weeks.
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The results of this proof-of-concept study suggest that IL-13emediated signaling pathways play an important role in the pathogenesis of AD, and the blockade of this cytokine could lead to significant clinical benefit. Patients with moderate-to-severe AD showed improvements with lebrikizumab treatment, even with single doses and twice daily TCS use. However, the twice-daily use of TCS before and during this trial in all study groups impaired the ability to fully assess the efficacy of lebrikizumab in AD, and monotherapy studies may be needed to assess the efficacy of lebrikizumab. The doseresponse relationships and kinetics of response observed in this study suggest that future studies of longer duration with loading, higher and potentially less frequent dosing, and a larger population on different (or without) background regimens will help clarify the role of targeting IL-13 with lebrikizumab in AD.
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SUPPLEMENTARY APPENDIX SUPPLEMENTARY METHODS
Study design
This study included a 2-week topical corticosteroid (TCS) run-in period prior to the 12-week treatment period, with the goal of standardizing the background therapy before randomization and demonstrating failure to respond to TCS alone. To assess TCS adherence, patients were required to record medication use in e-Diary devices.
The study was undertaken in accordance with Good Clinical Practice guidelines and adhered to the Declaration of Helsinki. All study documents and procedures were approved by the appropriate institutional review boards and ethics committees at each study site, and each patient provided written informed consent before study participation. An internal monitoring committee was incorporated to monitor patient safety throughout the study.
Patients
Eligible patients had a diagnosis of moderate-tosevere AD as graded by the Rajka-Langeland criteria present for at least 1 year at screening.
In addition to those stated in the manuscript, key exclusion criteria included past and/or current use of any IL-13 or IL-4/IL-13 monoclonal antibody and a clinically significant abnormality on screening electrocardiogram or laboratory tests.
Randomization and masking
Three active doses were included to characterize both exposureeresponse relationships and dosing frequency requirements. A blocked randomization scheme stratified by region was used with a block size of 4. To maintain blinding, a placebo arm was included, and all patients were administered 2 prefilled syringes on day 1. Placebo patients received two 1-mL syringes filled with placebo, lebrikizumab 125 mg patients received one 1-mL syringe of lebrikizumab 125 mg/mL and one 1-mL syringe of placebo, and lebrikizumab 250 mg patients received two 1-mL syringes of lebrikizumab 125 mg/mL. All randomized patients received a total of 4 subcutaneous injections: 2 on day 1, 1 on day 29, and 1 on day 57, ie, 3 doses of study drug (lebrikizumab or placebo) over the first 8 weeks of the 12-week blinded treatment period. Placebo was prepared with the same formulation as lebrikizumab without addition of the active agent, and both formulations were identical in appearance.
Procedures
Assessments occurred on weeks 1, 4, 6, 8 , and 12 during the 12-week treatment period. Days 1, 29, and 57 (weeks 1, 4, and 8) were treatment days, during which assessments were carried out before study drug administration. The Dermatology Life Quality Index and Atopic Dermatitis Impact Questionnaire (ADIQ) were self-administered at the study site before other nonpatient-reported outcome assessments. A study completion visit was performed at the end of week 20. The use of TCS other than that provided was prohibited.
As anaphylaxis, anaphylactoid, and hypersensitivity reactions are considered a potential risk with all biologic medications, all potential cases were identified and sent for adjudication by an independent lebrikizumab Anaphylaxis Adjudication Committee.
Pharmacokinetics
Serum samples for analysis of lebrikizumab pharmacokinetics were obtained in all patients at day 1 (pre-dose) and at weeks 1, 4 (pre-dose), 6, 8 (predose), 12, 16 , and 20 for all dosing regimens. Serum lebrikizumab concentrations were summarized by treatment and visit by using descriptive statistics for the patients that received 1 of the lebrikizumab treatment regimens. The reported pharmacokinetic parameters included the week 1 C max ; C min at weeks 4, 8, and 12 ; and the elimination half-life.
Outcomes
In addition to those stated in the manuscript, key secondary efficacy endpoints included the percent change from baseline in Eczema Area and Severity Index (EASI) score at week 12; percent change from baseline in SCORing Atopic Dermatitis (SCORAD) at week 12; percent change from baseline in total % body surface area (BSA) affected at week 12; percent change from baseline in itch as measured by SCORAD pruritus Visual Analog Scale (VAS) at week 12; and absolute and percent change in Dermatology Life Quality Index and ADIQ.
Other analyses included percent change in SCORAD, sleep loss VAS, as well as percentage of patients with an absolute change in pruritus VAS $3 from baseline, where the threshold of 3 was based on the minimum clinically important difference for that instrument.
The ADIQ is an atopic dermatitis (AD)especific measure of health-related quality of life for use in patients aged $12 years, developed by Genentech/ Roche following US Food and Drug Administration patient-reported outcome Guidance (2009).
Statistical analyses
Enrollment of 50 patients per treatment group was estimated to provide at least 90% power to detect a 40% difference in the proportion of patients with EASI-50 between each lebrikizumab group and the placebo group at week 12, under the assumption of a two-sided type I error rate of 0.05, a dropout rate of 20%, and an EASI-50 rate at week 12 in the placebo group of ;20%.
Statistical analyses of all endpoints related to a binary outcome used the same methodology as described for the primary endpoint. Point estimates of the proportions by treatment group, corresponding differences from placebo, and associated twosided 95% confidence intervals (CIs) for differences in proportions were provided.
Change from baseline for continuous endpoints was analyzed by using a mixed-effects model for repeat measures, including fixed effects of baseline value, treatment group, visit, treatment by visit interaction, and geographic region; the variable patient was included in the model as random effects with unstructured covariance structure. Missing data were implicitly imputed by the model (assuming missing at random). The 95% CIs and two-sided P values were reported for all secondary efficacy endpoints. No adjustments for multiplicity were made. All analyses were performed using SAS. An internal monitoring committee was incorporated to monitor patient safety throughout the study.
SUPPLEMENTARY RESULTS
Trial patients
A total of 294 patients were assessed for eligibility; 82 were ineligible and 212 patients were randomized. Of the 212 patients randomized, 209 received study drug. Among enrolled and treated patients, the mean age (standard deviation) at baseline was 36.1 6 12.6 years; 35% were women and 72% were white. Patients had on average 47% of their BSA affected, an average SCORAD of 59, and an EASI of 25. These baseline severity scores were already improved in comparison to screening due to the 2-week run-in period with twice-daily TCS application (Supplemental Table II ). The most common reason for screen failure (26 of 82 [31.7%] screenfailed patients) was patients not meeting the inclusion criterion of EASI score $14 due to improvements in EASI score during the run-in period.
Efficacy during safety follow-up
Overall, exploratory analyses showed that the proportion of patients maintaining EASI-50 (90.5%), EASI-75 (75.0%), and IGA 0 or 1 (70.6%) responses with lebrikizumab 125 mg every 4 weeks from week 12 to week 20 followed a similar pattern to that observed at week 12 (Supplemental Table V) . Dosedependent responses were also observed for percent change from baseline pruritus VAS at week 20.
Pharmacokinetics
The mean pharmacokinetic parameters and respective standard deviations for each of the lebrikizumab dosing regimens are shown in Supplemental Table VI (available at http://www. jaad.org). As expected, the pharmacokinetics of lebrikizumab in AD patients were linear and doseproportional over the dose range tested. The pharmacokinetics of lebrikizumab was also consistent with that of previous studies in adult asthma, S1-S4 showing linear, dose-proportional characteristics with a half-life of 19-22 days.
Safety
The rate of injection-site reactions was low in both the lebrikizumab-treated and placebo groups (1.3% and 1.9%, respectively). Herpes infections occurred infrequently and only in lebrikizumab-treated patients (6 [3.8%] ; herpes simplex in 4 [2.6%] , and herpes zoster in 2 [1.3%] ); all events were nonserious, mild in intensity, and resolved by the end of the study. There were no events of eczema herpeticum. Five (3.2%) lebrikizumab-treated patients reported eosinophilassociated adverse events (AEs; 3 events of eosinophilia and 2 events of eosinophil count increased); all events were nonserious and mild-to-moderate in intensity. There were no associated clinical symptoms noted with these 5 AEs. The maximum eosinophil count in these 5 patients ranged 1.0-3.2 3 10 9 /L; of these, 3 were grade 2 eosinophilia (1501-5000 cell/ mm 3 ). The increases observed were in line with what has been seen in previous lebrikizumab studies. S2,S5 Given the previous imbalances reported in biologic trials in AD, S6 we evaluated conjunctivitis. A total of 15 (9.6%) patients in the pooled lebrikizumab group and 4 patients (7.5%) in the placebo group had conjunctivitis as an AE; all events were nonserious, none led to treatment discontinuation, and there was not a doseresponse relationship. (4) 3 (2) 1 ( Patients with skin infection 6 (11) 5 (10) 3 (6) 14 (9) 9 (17) Herpes infections
Supplemental
Patients with $1 infection, n (%) 1 (2) 3 (6) 2 (4) 6 (4) 0 (0) Total number of infections related to study drug Patients with $1 AE, n (%) 7 (13) 5 (10) 3 (6) 15 (10) 4 (8) Total number of events 8 6 4 18 4 Conjunctivitis allergic, n (%) 4 (7) 2 (4) 2 (4) 8 (5) 0 (0) Conjunctival hyperaemia, n (%) 0 (0) 1 (2) 0 (0) 1 (1) 0 (0) AE, Adverse event; Q4W, every 4 weeks; SAE, serious adverse event. *The following AEs led to withdrawal from study drug: skin infection in the 125 mg single dose group, anxiety and myopathy in 125 mg Q4W group, and atopic dermatitis in the placebo group. y One (1%) patient in the 250 mg single dose lebrikizumab group experienced an AE (gastrointestinal viral infection) that led to dose interruption. z Members of the lebrikizumab Anaphylaxis Adjudication Committee reviewed blinded data to adjudicate cases as anaphylaxis per Sampson criteria.
x Infections related to study drug were investigator-assessed. BSA, Body surface area; CI, confidence interval; EASI-50, 50% reduction in Eczema Area Severity Index; EASI-75, 75% reduction in Eczema Area Severity Index; IGA, Investigator Global Assessment; Q4W, every 4 weeks; SCORAD-50, 50% reduction in SCORing Atopic Dermatitis; SE, standard error; VAS, Visual Analog Scale.
